All sponsors

Ocugen

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING1
READOUTS ≤12 MONTHS2
Open Ocugen on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ArMaDa
NCT06018558
P1/2Active, not recruitingGeographic Atrophy602026-02-03 (-2 mo)
GARDian3
NCT05956626
P2/3Active, not recruitingStargardt Disease512026-09-28 (+11 mo)
liMeliGhT
NCT06388200
P3Active, not recruitingRetinitis Pigmentosa1402027-02-12 (+19 mo)
OCU400 Low Dose
NCT05203939
P1/2Active, not recruitingRetinitis Pigmentosa; Leber Congenital Amaurosis222027-03 (+47 mo)
OCU410
NCT07770828
P3RecruitingDry Age-related Macular Degeneration2372028-07-30